UPDATE: Oppenheimer Starts Celularity (CELU) at Outperform

January 27, 2022 4:03 PM EST
Get Alerts CELU Hot Sheet
Price: $7.87 +10.07%

Rating Summary:
    1 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 13 | New: 20
Trade Now! 
Join SI Premium – FREE
(Updated - January 27, 2022 4:04 PM EST)

Oppenheimer analyst Matthew Biegler initiates coverage on Celularity (NASDAQ: CELU) with a Outperform rating and a price target of $9.00.

The analyst comments "We are initiating on Celularity with an Outperform rating and $9 PT, based on our enthusiasm for the company’s unique allogeneic approach to cancer cell therapy. Celularity has perfected methods that turn donor placentas—an oft-discarded tissue—into a scalable source of off-the-shelf NK and T-cell therapies. While the answer to the question “which allogeneic source is the best allogeneic source” is probably nuanced, we are fans of Celularity’s development focus in consolidation AML and are bullish on the prospects of NK-cell therapy in AML more broadly. Meanwhile, preclinical data from CyCART-19 point to improvements in persistence—potentially addressing the nagging issue of response durability presently weighing on the allogeneic CAR-T field."

For an analyst ratings summary and ratings history on Celularity click here. For more ratings news on Celularity click here.

Shares of Celularity closed at $4.17 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage